Comparison of adverse risk factors between POD cohort, ZUMA-2, and US consortium data sets
| Phase of care . | Post–CAR-T POD . | Pre–CAR-T . | ||
|---|---|---|---|---|
| Cohort | Epstein-Peterson et al | ZUMA-2 | US Lymphoma CAR T Consortium | |
| Subgroup | Patients with POD after CAR-T therapy | All CAR-T recipients | All CAR-T recipients | |
| n | 135 | 68 | 168 | |
| Age, median (range), y | 62 (32-82) | 65 (38-79) | 67 (34-89) | |
| Number of prior therapies | 3 (1-9) | 3 (1-5) | 3 (1-10) | |
| Refractory to immediate therapy before CAR-T infusion | 57% | 40% | 44% | |
| TP53 mutation | 21/41 (51%) | 54/79 (68%) | 6/26 (17%) | 46/99 (46%) |
| Ki67 ≥30% | 64/65 (98%) | 96/114 (84%) | 40/49 (82%) | 118/152 (78%) |
| Blastoid/pleomorphic morphology | 42/78 (54%) | 59/135 (44%) | 21/68 (31%) | 68 /168 (40%) |
| Phase of care . | Post–CAR-T POD . | Pre–CAR-T . | ||
|---|---|---|---|---|
| Cohort | Epstein-Peterson et al | ZUMA-2 | US Lymphoma CAR T Consortium | |
| Subgroup | Patients with POD after CAR-T therapy | All CAR-T recipients | All CAR-T recipients | |
| n | 135 | 68 | 168 | |
| Age, median (range), y | 62 (32-82) | 65 (38-79) | 67 (34-89) | |
| Number of prior therapies | 3 (1-9) | 3 (1-5) | 3 (1-10) | |
| Refractory to immediate therapy before CAR-T infusion | 57% | 40% | 44% | |
| TP53 mutation | 21/41 (51%) | 54/79 (68%) | 6/26 (17%) | 46/99 (46%) |
| Ki67 ≥30% | 64/65 (98%) | 96/114 (84%) | 40/49 (82%) | 118/152 (78%) |
| Blastoid/pleomorphic morphology | 42/78 (54%) | 59/135 (44%) | 21/68 (31%) | 68 /168 (40%) |